Get the Stockscreener App
4.52
3.21%
-0.15
After Hours:
4.60
0.08
+1.77%
Reshape Lifesciences Inc stock is traded at $4.52, with a volume of 21,792.
It is down -3.21% in the last 24 hours and down -1.53% over the past month.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
See More
Previous Close:
$4.67
Open:
$4.8
24h Volume:
21,792
Relative Volume:
0.27
Market Cap:
$3.30M
Revenue:
$9.81M
Net Income/Loss:
$-26.16M
P/E Ratio:
-0.1166
EPS:
-38.77
Net Cash Flow:
$-17.45M
1W Performance:
+0.44%
1M Performance:
-1.53%
6M Performance:
-66.60%
1Y Performance:
-65.52%
1-Day Range:
$4.52
$4.859
1-Week Range:
$4.35
$5.19
52-Week Range:
$4.09
$29.00
Reshape Lifesciences Inc Stock (RSLS) Company Profile
Name
Reshape Lifesciences Inc
Sector
Industry
Phone
949-429-6680
Address
1001 CALLE AMANECER, SAN CLEMENTE
Compare RSLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RSLS
Reshape Lifesciences Inc
|
4.52 | 3.30M | 9.81M | -26.16M | -17.45M | -38.77 |
|
ABT
Abbott Laboratories
|
113.48 | 196.83B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
383.42 | 146.17B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
98.66 | 145.41B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.08 | 112.94B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.78 | 41.16B | 6.60B | 4.16B | 490.10M | 6.93 |
Reshape Lifesciences Inc Stock (RSLS) Latest News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GLXZ, R - GuruFocus.com
ReShape Lifesciences updates on merger with Vyome Therapeutics - TipRanks
ReShape and Vyome to merge in all-stock deal By Investing.com - Investing.com Australia
ReShape and Vyome to merge in all-stock deal - Investing.com
ReShape Lifesciences® Provides Update on Merger Agreement - GlobeNewswire
ReShape Lifesciences Merges with Vyome, Sells Core Medical Device Portfolio to Biorad - StockTitan
Obesity Treatment Market is Booming Worldwide | Pfizer, Nutrisystem, Roche, - openPR
Rising Burden of Neurological Disorders in Emerging Economies Fuels Demand for Vagus Nerve Stimulation Therapy - PharmiWeb.com
Vagus Nerve Stimulators Market Growth in Future Scope 2024-2031 - openPR
Global Bariatric Surgery Devices Market Set For 9.3% Growth, Reaching $2.98 Billion By 2028 - NEWS CHANNEL NEBRASKA
Synthetic Biosensors Market Set to Witness Steady Growth through (2024-2031) - WhaTech
RSLS Stock Touches 52-Week Low at $4.48 Amid Market Challenges By Investing.com - Investing.com South Africa
ReShape Lifesciences Announces Merger and Asset Sale Plans - TipRanks
RSLS Stock Touches 52-Week Low at $4.48 Amid Market Challenges - Investing.com
Bariatric Surgery Devices Market is expected to grow at a CAGR - openPR
ReShape Lifesciences faces Nasdaq delisting over equity shortfall - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENV, RS - GuruFocus.com
Bariatric Surgery Devices Market Global Forecasts Report and Company Analysis 2025-2033, Featuring Apollo Endosurgery, GI Dynamics, Intuitive Surgical, J&J, Medtronic, Olympus, Reshape, TransEnterix - GlobeNewswire
Weight-Loss Devices Market Will Drive an Exponential CAGR - openPR
Intragastric Balloons Market Size to Surpass USD 160.7 - GlobeNewswire
Earnings call: ReShape Lifesciences reports growth and strategic mergers - Investing.com
Earnings call: ReShape Lifesciences reports growth and strategic mergers By Investing.com - Investing.com Canada
ReShape Lifesciences Inc (RSLS) Quarterly 10-Q Report - Quartzy
ReShape Lifesciences Reports Q3 Growth and Strategic Moves - TipRanks
ReShape Lifesciences® Reports Third Quarter Ended September - GlobeNewswire
ReShape Lifesciences Reports 16.6% Revenue Growth, Inks $5.16M Asset Sale Deal | RSLS Stock News - StockTitan
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update - The Manila Times
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and - The Bakersfield Californian
Gastric Electrical Stimulators Market Size, Share and Growth - openPR
Health Canada approves ReShape's Lap-Band 2.0 FLEX By Investing.com - Investing.com Australia
FibroGen Reports Third Quarter 2024 Financial Results - The Manila Times
ReShape Lifesciences® to Announce Financial Results for the - GlobeNewswire
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - The Manila Times
ReShape Lifesciences (RSLS) Sets Q3 2024 Earnings Call with Post-Merger Chairman | RSLS Stock News - StockTitan
ReShape secures NIH grant to develop electrodes for diabetes treatment device - Medical Device Network
Health Canada approves ReShape's Lap-Band 2.0 FLEX - Investing.com
ACNB Corporation Receives Regulatory Approvals to Acquire Traditions Bancorp, Inc. - The Manila Times
Costco Wholesale (COST-Q) QuotePress Release - The Globe and Mail
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX - GlobeNewswire
ReShape's Lap-Band 2.0 FLEX Secures Health Canada Approval, Expands Market Reach | RSLS Stock News - StockTitan
Next-Generation Diabetes-Managing Innovations - Trend Hunter
Banzai Regains Compliance with Nasdaq Minimum Market Value of Publicly Held Shares Requirement - The Manila Times
ReShape Lifesciences receives NIH supplementary grant with CARSS - TipRanks
ReShape Lifesciences® Receives NIH Supplementary Grant with - GlobeNewswire
ReShape Lifesciences Secures $241K NIH Grant for Breakthrough Diabetes Device Development | RSLS Stock News - StockTitan
Inuvo Reports 23% Sequential Revenue Growth in Q3 2024On November 8, 2024, Inuvo, Inc. (NYSE American: INUV) released its financial performance for the third quarter of 2024, showcasing a substantial 23% sequential revenue increase to $22.4 million c - Defense World
Enphase Energy Inc (ENPH-Q) QuotePress Release - The Globe and Mail
Johnson & Johnson (JNJ-N) QuotePress Release - The Globe and Mail
Brookfield Asset Management Ltd (BAM-N) QuotePress Release - The Globe and Mail
(RSLS) Technical Pivots with Risk Controls - Stock Traders Daily
Qualcomm Inc (QCOM-Q) QuotePress Release - The Globe and Mail
Reshape Lifesciences Inc Stock (RSLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):